Digital health company Hims & Hers plans to offer custom versions of wildly popular weight loss shots even after supply ...
US drug regulators have turned down Ipsen's effort to slow down generic competition for its blockbuster drug Somatuline Depot ...
Zealand Pharma appears to have taken a small step forward with a candidate that targets both GLP-1 and GLP-2, an approach ...
Jean-Paul Clozel is ready to pass the torch at his Actelion follow-up Idorsia, but he doesn’t want to walk away from the ...
Nimbus Therapeutics closed one of the biggest single-drug deals in biotech, selling its TYK2 inhibitor to Takeda for $4 ...
An experimental prostate cancer drug developed by Johnson & Johnson that uses a rare radioactive particle called actinium-225 ...
No­vo Nordisk’s semaglu­tide hit its sec­ondary end­points in the Phase 3 FLOW tri­al, demon­strat­ing a re­duc­tion in the ...
As Johnson & Johnson attempts to settle tens of thousands of talc lawsuits, a group of five plaintiffs filed new litigation ...
Finding a way to deliver genetic medicines to the right parts of the body is one of the most technologically vexing problems ...
Nuvation Bio showcased longer-term Phase 2 data around the next-gen ROS1 inhibitor it hopes will give Pfizer and Bristol ...
SR One, a life sciences venture capital firm that years ago split from GSK, has raised more than $200 million for a growth ...
When Pfizer laid out the ambitious vision for its new oncology division in February, it announced that it was taking the ...